Synthetic modifications of the immunomodulating peptide thymopentin to confer anti-mycobacterial activity

Biomaterials

Volumn 35, Issue 9, 2014, Pages 3102-3109

  Wang, Ying ^a   Ke, Xi Yu ^b   Khara, Jasmeet S ^a   Bahety, Priti ^a   Liu, Shaoqiong ^b   Seow, See Voon ^c   Yang, Yi Yan ^b   Ee, Pui Lai Rachel ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b INSTITUTE OF BIOENGINEERING AND NANOTECHNOLOGY   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Cationic peptides; Drug resistance; Immunotherapeutics; Mycobacterium smegmatis; Synergy; Thymopentin

Indexed keywords

CATIONIC PEPTIDES; DRUG RESISTANCE; IMMUNOTHERAPEUTICS; MYCOBACTERIUM SMEGMATIS; SYNERGY; THYMOPENTIN;

AMINO ACID SEQUENCE; ANIMALS; ANTI-BACTERIAL AGENTS; COLONY COUNT, MICROBIAL; DRUG RESISTANCE, BACTERIAL; HEMOLYSIS; HUMANS; IMMUNOLOGIC FACTORS; MACROPHAGES; MICE; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, CONFOCAL; MOLECULAR SEQUENCE DATA; MYCOBACTERIUM SMEGMATIS; PEPTIDES; RATS; RIFAMPIN; THYMOPENTIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84895008056     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.12.049     Document Type: Article

References (44)

1. WHO Global tuberculosis report 2013 2013, World Health Organization, Geneva.
2. Walter N.D., Strong M., Belknap R., Ordway D.J., Daley C.L., Chan E.D. Translating basic science insight into public health action for multidrug- and extensively drug-resistant tuberculosis. Respirology 2012, 17:772-791.
3. Pawlowski A., Jansson M., Skold M., Rottenberg M.E., Kallenius G. Tuberculosis and HIV co-infection. PLoS Pathog 2012, 8:e1002464.
4. Gurumurthy P., Ramachandran G., Hemanth Kumar A.K., Rajasekaran S., Padmapriyadarsini C., Swaminathan S., et al. Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis. Clin Infect Dis 2004, 38:280-283.
5. Afacan N.J., Yeung A.T., Pena O.M., Hancock R.E. Therapeutic potential of host defense peptides in antibiotic-resistant infections. Curr Pharm Des 2012, 18:807-819.
6. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 2002, 415:389-395.
7. Marr A.K., Gooderham W.J., Hancock R.E. Antibacterial peptides for therapeutic use: obstacles and realistic outlook. Curr Opin Pharmacol 2006, 6:468-472.
8. Fjell C.D., Hiss J.A., Hancock R.E., Schneider G. Designing antimicrobial peptides: form follows function. Nat Rev Drug Discov 2012, 11:37-51.
9. Mookherjee N., Hancock R.E. Cationic host defence peptides: innate immune regulatory peptides as a novel approach for treating infections. Cell Mol Life Sci. 2007, 64:922-933.
10. Goldstein G., Audhya T.K. Thymopoietin to thymopentin: experimental studies. Surv Immunol Res. 1985, 4(Suppl. 1):1-10.
11. Goldstein G., Scheid M.P., Boyse E.A., Schlesinger D.H., Van Wauwe J. A synthetic pentapeptide with biological activity characteristic of the thymic hormone thymopoietin. Science 1979, 204:1309-1310.
12. Audhya T., Scheid M.P., Goldstein G. Contrasting biological activities of thymopoietin and splenin, two closely related polypeptide products of thymus and spleen. Proc Natl Acad Sci U S A 1984, 81:2847-2849.
13. Conant M.A., Calabrese L.H., Thompson S.E., Poiesz B.J., Rasheed S., Hirsch R.L., et al. Maintenance of CD4+ cells by thymopentin in asymptomatic HIV-infected subjects - results of a double-blind, placebo-controlled study. Aids 1992, 6:1335-1339.
14. Coppola S., Buccoliero G., Laddago V., Monno L., Perrone A., Guida G., et al. Topical thymopentin therapy in HIV positive patients with recurrent oral candidiasis: a pilot study. New Microbiol. 1996, 19:351-355.
15. Merigan T.C., Hirsch R.L., Fisher A.C., Meyerson L.A., Goldstein G., Winters M.A. The prognostic significance of serum viral load, codon 215 reverse transcriptase mutation and CD4+ T cells on progression of HIV disease in a double-blind study of thymopentin. Aids 1996, 10:159-165.
16. Jiao Q., Wang B., Zhang R.L., Wang B.G., Feng L.M., Wang H.J., et al. Clinical controlled study of integrative Chinese and western medicine in treating 49 cases of SARS. Chin J Integr Med 2003, 9:175-180.
17. Hsieh K.H., Shaio M.F., Liao T.N. Thymopentin treatment in severe atopic-dermatitis clinical and immunological evaluations. Arch Dis Child 1992, 67:1095-1102.
18. Kantharia B.K., Goulding N.J., Hall N.D., Davies J., Maddison P.J., Bacon P.A., et al. Thymopentin (TP-5) in the treatment of rheumatoid arthritis. Br J Rheumatol 1989, 28:118-123.
19. Leung D.Y., Hirsch R.L., Schneider L., Moody C., Takaoka R., Li S.H., et al. Thymopentin therapy reduces the clinical severity of atopic dermatitis. J Allergy Clin Immunol 1990, 85:927-933.
20. Malaise M.G., Franchimont P., Bachandersen R., Gerber H., Stocker H., Hauwaert C., et al. Treatment of active rheumatoid-arthritis with slow intravenous injections of thymopentin - a double-blind placebo-controlled randomized study. Lancet 1985, 1:832-836.
21. Sundal E., Bertelletti D. Thymopentin treatment of rheumatoid-arthritis. Arzneimittelforschung 1994, 44-2:1145-1149.
22. Liu L., Xu K., Wang H., Tan P.J., Fan W., Venkatraman S.S., et al. Self-assembled cationic peptide nanoparticles as an efficient antimicrobial agent. Nat Nanotechnol 2009, 4:457-463.
23. Wang H., Xu K., Liu L., Tan J.P., Chen Y., Li Y., et al. The efficacy of self-assembled cationic antimicrobial peptide nanoparticles against Cryptococcus neoformans for the treatment of meningitis. Biomaterials 2010, 31:2874-2881.
24. Wiradharma N., Khoe U., Hauser C.A., Seow S.V., Zhang S., Yang Y.Y. Synthetic cationic amphiphilic α-helical peptides as antimicrobial agents. Biomaterials 2011, 32:2204-2212.
25. Huang Y., Wiradharma N., Xu K., Ji Z., Bi S., Li L., et al. Cationic amphiphilic alpha-helical peptides for the treatment of carbapenem-resistant Acinetobacter baumannii infection. Biomaterials 2012, 33:8841-8847.
26. Qiao Y., Yang C., Coady D.J., Ong Z.Y., Hedrick J.L., Yang Y.Y. Highly dynamic biodegradable micelles capable of lysing gram-positive and gram-negative bacterial membrane. Biomaterials 2012, 33:1146-1153.
27. Lienkamp K., Madkour A.E., Kumar K.N., Nusslein K., Tew G.N. Antimicrobial polymers prepared by ring-opening metathesis polymerization: manipulating antimicrobial properties by organic counterion and charge density variation. Chemistry 2009, 15:11715-11722.
28. Rand K., Houck H., Brown P., Bennett D. Reproducibility of the microdilution checkerboard method for antibiotic synergy. Antimicrob Agents Chemother 1993, 37:613-615.
29. Jacobs D.S., DeMott W.R., Oxley D.K. Jacobs & DeMott laboratory test handbook with key word index 2001, Lexi Comp, Hudson, OH. 5th ed.
30. Eliopoulos G.M., Moellering R.C. Antibiotic combinations 1991, The Williams & Wilkins Co., Baltimore, MD. 3rd ed.
31. Tencza S.B., Creighton D.J., Yuan T., Vogel H.J., Montelaro R.C., Mietzner T.A. Lentivirus-derived antimicrobial peptides: increased potency by sequence engineering and dimerization. J Antimicrob Chemother 1999, 44:33-41.
32. Miller M.A., Cloyd M.W., Liebmann J., Rinaldo C.R., Islam K.R., Wang S.Z., et al. Alterations in cell membrane permeability by the lentivirus lytic peptide (LLP-1) of HIV-1 transmembrane protein. Virology 1993, 196:89-100.
33. Sakai N., Matile S. Anion-mediated transfer of polyarginine across liquid and bilayer membranes. J Am Chem Soc. 2003, 125:14348-14356.
34. Mitchell D.J., Kim D.T., Steinman L., Fathman C.G., Rothbard J.B. Polyarginine enters cells more efficiently than other polycationic homopolymers. J Pept Res. 2000, 56:318-325.
35. NCCLS Methods for determining bactericidal activity of antimicrobial agents; approved guideline 1999, NCCLS, Wayne, Pennsylvania, USA.
36. Anantharaman A., Rizvi M.S., Sahal D. Synergy with rifampin and kanamycin enhances potency, kill kinetics, and selectivity of de novo-designed antimicrobial peptides. Antimicrob Agents Chemother 2010, 54:1693-1699.
37. Barriere S.L. Bacterial resistance to beta-lactams, and its prevention with combination antimicrobial therapy. Pharmacotherapy 1992, 12:397-402.
38. Wu Y.L., Scott E.M., Po A.L., Tariq V.N. Ability of azlocillin and tobramycin in combination to delay or prevent resistance development in Pseudomonas aeruginosa. J Antimicrob Chemother 1999, 44:389-392.
39. Cirioni O., Silvestri C., Ghiselli R., Orlando F., Riva A., Mocchegiani F., et al. Protective effects of the combination of alpha-helical antimicrobial peptides and rifampicin in three rat models of Pseudomonas aeruginosa infection. J Antimicrob Chemother 2008, 62:1332-1338.
40. Mangoni M.L., Rinaldi A.C., Di Giulio A., Mignogna G., Bozzi A., Barra D., et al. Structure-function relationships of temporins, small antimicrobial peptides from amphibian skin. Eur J Biochem 2000, 267:1447-1454.
41. Lunin S.M., Glushkova O.V., Khrenov M.O., Parfenyuk S.B., Novoselova T.V., Fesenko E.E., et al. Thymus peptides regulate activity of RAW 264.7 macrophage cells: inhibitory analysis and a role of signal cascades. Expert Opin Ther Targets 2011, 15:1337-1346.
42. Moller M., Hoal E.G. Current findings, challenges and novel approaches in human genetic susceptibility to tuberculosis. Tuberculosis (Edinb) 2010, 90:71-83.
43. Keane J., Gershon S., Wise R.P., Mirabile-Levens E., Kasznica J., Schwieterman W.D., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001, 345:1098-1104.
44. D'Haens G., Daperno M. Advances in biologic therapy for ulcerative colitis and Crohn's disease. Curr Gastroenterol Rep 2006, 8:506-512.